Among these pruritogens, particular attention has been paid to interleukin-31 (IL-31), since systemic administration of the anti-IL-31 receptor A (IL-31RA) antibody nemolizumab successfully ameliorates chronic itch in patients with atopic dermatitis and prurigo nodularis [10,11]. This evidence concerns the gene IL31 and atopic eczema.